Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 29:6:30659.
doi: 10.1038/srep30659.

Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice

Wei Yao  1 , Ji-Chun Zhang  1 , Tamaki Ishima  1 , Chao Dong  1 , Chun Yang  1 , Qian Ren  1 , Min Ma  1 , Mei Han  1 , Jin Wu  1 , Hiroyuki Suganuma  2 , Yusuke Ushida  2 , Masayuki Yamamoto  3 , Kenji Hashimoto  1
Affiliations

Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice

Wei Yao et al. Sci Rep. .

Abstract

The transcription factor Keap1-Nrf2 system plays a key role in inflammation which is involved in depression. We found lower expression of Keap1 and Nrf2 proteins in the prefrontal cortex (PFC), CA3 and dentate gyrus (DG) of hippocampus in mice with depression-like phenotype compared to control mice. Serum levels of pro-inflammatory cytokines in Nrf2 knock-out (KO) mice were higher than those of wild-type mice, suggestive of enhanced inflammation in KO mice. Decreased brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-receptor-kinase B (TrkB) signaling in the PFC, CA3 and DG plays a role in the depression-like phenotype of Nrf2 KO mice. TrkB agonist 7,8-dihydroxyflavone, but not antagonist ANA-12, produced antidepressant effects in Nrf2 KO mice, by stimulating TrkB in the PFC, CA3 and DG. Pretreatment with Nrf2 activator sulforaphane (SFN) prevented the depression-like phenotype induced after repeated social defeat stress. Interestingly, dietary intake of 0.1% glucoraphanin (a precursor of SFN) containing food during juvenile and adolescent stages also prevented the depression-like phenotype evoked in adulthood, after repeated social defeat stress. These findings suggest that Keap1-Nrf2 system plays a key role in depression and that dietary intake of SFN-rich food during juvenile stages and adolescence can confer stress resilience in adulthood.

PubMed Disclaimer

Conflict of interest statement

Drs H. Suganuma and Y. Ushida are employee of KAGOME CO., LTD which provides GF-rich extract powder. The other authors declare no competing financial interest.

Figures

Figure 1
Figure 1. Potentiation of neurite outgrowth by SFN.
(a) Representative photographs of microtubule-associated protein 2 (MAP-2) immunocytochemistry in PC12 cells. Control: NGF (2.5 ng ml−1) alone, SFN: NGF (2.5 ng ml−1) + SFN (1.0 μM). (b) Effects of SFN on NGF-induced neurite outgrowth in PC12 cells. SFN (0.01, 0.1 or 1.0 μM) potentiated NGF-induced neurite outgrowth in PC12 cells, in a concentration-dependent manner. All data represent the mean ± S.E.M. (n = 6–12) *P < 0.05, ***P < 0.001 as compared with the control group (one-way ANOVA). (c) The potentiating effects of SFN (1.0 μM) on NGF-induced neurite outgrowth were significantly antagonized by treatment with Nrf2 siRNA, but not negative siRNA. Neither Nrf2 siRNA nor negative siRNA alone altered NGF (2.5 ng ml−1)-induced neurite outgrowth. All data represent the mean ± S.E.M. (n = 8). ***P < 0.001 as compared with the SFN (1.0 μM) group (one-way ANOVA). (d) The potentiating effects of SFN (1.0 μM) on Nrf2 protein levels were significantly antagonized by treatment with Nrf2 siRNA, but not the negative siRNA. In contrast, neither Nrf2 siRNA nor negative siRNA alone altered levels of Nrf2 protein in the control (NGF (2.5 ng ml−1)-treated) group. All data represent the mean ± S.E.M. (n = 4). *P < 0.05, **P < 0.01 as compared with the SFN (1.0 μM) group (one-way ANOVA).
Figure 2
Figure 2. Protein levels of Keap1 and Nrf2 in the brain from mice with depression-like phenotype.
(a,b) The levels of Keap1 and Nrf2 proteins in the mouse brain regions from social defeat stress (susceptible) mice and control mice (n = 5 or 6). Data represent the mean ± S.E.M. *P < 0.05 and **P < 0.01 compared with the control group (Student t-test).
Figure 3
Figure 3. Depression-like phenotypes of Nrf2 KO mice and inflammation in Nrf2 KO mice.
(a) The behavior tests in WT and Nrf2 KO mice. Locomotion (LMT); tail-suspension test (TST); forced swimming test (FST), 1% sucrose preference test (SPT) and total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M (n = 9 or 10). *P < 0.05, **P < 0.01 compared with the WT group (Student t-test). (b,c) Western blot of BDNF, p-TrkB/TrkB, GluA-1 and PSD-95 in WT and Nrf2 KO mice. Data represent the mean ± S.E.M (n= 6 or 7). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group (Student t-test). (d) Serum levels of TNF-α, IL-6, IL-10 and IL-1β in WT and Nrf2 KO mice. Data represent the mean ± S.E.M (n = 9–12). *P < 0.05, **P < 0.01 compared with the WT group (Student t-test).
Figure 4
Figure 4. Antidepressant effect of 7,8-DHF, a TrkB agonist, in Nrf2 KO mice.
(a) 7,8-DHF (10 mg/kg) or vehicle (10 ml/kg) was administered i.p. into WT and Nrf2 KO mice. Behavioral tests were performed 1 hour after injection. Locomotion (LMT); tail-suspension test (TST); forced swimming test (FST), 1% sucrose preference test (SPT) and total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M. (n = 9–11). *P < 0.05, **P < 0.01, ***P < 0.001 compared with vehicle-treated KO group (two-way ANOVA). (b) Levels of p-TrkB/TrkB ratio in the mouse brain regions after injection of 7,8-DHF. Data represent the mean ± S.E.M (n = 5 or 6). **P < 0.01, ***P < 0.001 compared with vehicle-treated KO group (two-way ANOVA). (c) ANA-12 did not show antidepressant effect in the Nrf2 KO mice. ANA-12 (0.5 mg/kg) or vehicle (10 ml/kg) was administered i.p. into WT and Nrf2 KO mice. Behavioral tests were performed 1 hour after injection. Locomotion (LMT); tail-suspension test (TST); forced swimming test (FST); 1% sucrose preference test (SPT) and total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M. (n = 8–11). *P < 0.05, **P < 0.01, ***P < 0.001 compared with vehicle-treated KO group (two-way ANOVA). (d) SFN did not show antidepressant effect in the Nrf2 KO mice. SFN (10 mg/kg) or vehicle (10 ml/kg) was administered i.p. into WT and Nrf2 KO mice. Behavioral tests were performed 1 hour after injection. Locomotion (LMT); tail-suspension test (TST); forced swimming test (FST), 1% sucrose preference test (SPT) and total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M. (n = 10–11). **P < 0.01, ***P < 0.001 compared with vehicle-treated KO group (two-way ANOVA).
Figure 5
Figure 5. Pretreatment with SFN prevents depression after repeated social defeat stress.
(a) The schedule of treatment and behavioral evaluations. (b) Social interaction test (SIT): no target, (c) SIT: target. (d) 1% sucrose preference test (SPT), (e) total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M. (n = 10–14). *P < 0.05, ***P < 0.001 compared with the vehicle-treated stress group (two-way ANOVA). (f,g) Western blot of Keap1, Nrf2 in the mouse brain regions. Data represent the mean ± S.E.M. (n = 5 or 6). *P < 0.01, **P < 0.01, ***P < 0.001 compared with the vehicle-treated stressed group (two-way ANOVA). (h,i) Western blot of BDNF, p-TrkB/TrkB in the mouse brain regions. Data represent the mean ± S.E.M. (n = 5 or 6). *P < 0.01, **P < 0.01, ***P < 0.001 compared with the vehicle-treated stress group (two-way ANOVA).
Figure 6
Figure 6. Dietary intake of 0.1% GP during the juvenile and adolescence prevents depression after repeated social defeat stress.
(a) The schedule of dietary intake of 0.1% glucoraphanin (GP) and behavioral evaluations. (b) Social interaction test (SIT): no target, (c) SIT: target, (d) 1% sucrose preference test (SPT), (e) total fluid intake test (FIT) for SPT. Data represent the mean ± S.E.M. (n = 16 or 17). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the vehicle-treated stressed group (two-way ANOVA).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Whiteford H. A. et al.. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382, 1575–1586 (2013). - PubMed
    1. Walker E. R., McGee R. E. & Druss B. G. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72, 334–341 (2015). - PMC - PubMed
    1. Mukakami K. & Sasaki S. Dietary intake and depressive symptoms: a systemic review of observational studies. Mol Nutr Food Res. 54, 471–488 (2010). - PubMed
    1. Bazinet R. P. & Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 15, 771–785 (2014). - PubMed
    1. Mello A. H. et al.. ω-3 and major depression: a review. Acta Neuropsychiatr 26, 178–185 (2014). - PubMed

Publication types